Safety of Transcutaneous Electrical Stimulation Potentiating Recovery in Acute Spinal Cord Injury Syndromes

Details

Spinal cord injury (SCI) is often devastating, as many SCI patients are permanently disabled resulting in decades of lost productivity and quality adjusted life years. Patients must largely rely on supportive care, as no Federal Drug Administration (FDA)- approved therapy to treat aSCI exists. Even with early aggressive physical therapy, voluntary movement below the level of the lesion is limited or even absent. There is critical unmet need for strategies to preserve neural function and prevent the host of complications in the hyperacute phase after SCI until discharge to acute rehabilitation. In the proposed project, Safety of Transcutaneous Electrical stimulation Potentiating Recovery in Acute spinal cord Injury SyndromEs (STEP-RAISE), we will conduct a combined Phase 1 and Phase 2 pilot clinical trial of non-invasive transcutaneous spinal cord stimulation (tSCS), and track the course of neurophysiological recovery following aSCI with granular objective outcome measures to determine whether implementation of early tSCS below the level of lesion can safely augment the functional recovery. Specific Aims: Aim 1: Test the safety of tSCS applied below the level of injury to the lumbosacral spinal cord after acute spinal cord injury, starting 72 hours after injury. We hypothesize that there will be no adverse events associated with acute application of tSCS. To assess safety, we will quantify the impacts of tSCS on hemodynamics, spinal cord perfusion pressure (SCPP), and monitor for local skin site reactions. Aim 2: Demonstrate the proof-of-principle that tSCS application in the acute phase post-injury can potentiate recovery. We hypothesize that tSCS can improve volitional movement and/or sensation acutely after SCI as measured by an improved American Spinal Injury Association Impairment Score (ASIA) score in the presence of tSCS. Aim 3: Identify novel treatment-related mechanistic biomarkers (exploratory). We hypothesize that there will be fluid-based biomarkers that will change in the setting of tSCS receipt. We will quantify the trajectory of neuronal ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial cell glial fibrillary acidic protein (GFAP) injury markers in the blood and cerebrospinal fluid (CSF) using next generation, high-throughput Olink proteomics (\> 5,400 proteins). Transcutaneous spinal stimulation will be delivered using the experimental ARC-EX device (ONWARD Medical), via skin surface electrodes placed over the spine (stimulating electrodes) and bilaterally on the iliac crests (reference electrodes) during the intervention. The stimulation protocol in this study will be adapted from previously described protocols. Based on previous studies on safety and efficacy of tSCS, we will use biphasic waveforms with a burst frequency of 30 Hz, a carrier frequency of 10 kHz, with a pulse width of 100µs. The neurophysiological assessments described above will be used to characterize the intensity of the stimulation necessary to reach the threshold to elicit muscle responses. Stimulation will be delivered below the identified motor threshold (subthreshold stimulation intensity) continuously for 60 minutes once a day for 5 days. The intensity of the stimulation will be increased gradually (e.g., 5 mA steps) every session to the motor threshold intensity. Increase in trunk/lower extremity muscle tone will be additionally monitored to assess whether the amplitude of stimulation required to reach motor threshold changes with days post injury + tSCS treatment. If no motor evoked potentials (MEP) can be elicited due to spinal shock, the stimulation intensity will be chosen based on previously reported ranges of effective stimulation, including those observed in our ongoing clinical trial in patients with chronic low back pain (NCT05265000) which provides ranges of maximum tolerable stimulation intensities in individuals without SCI, who have full sensation. The specific stimulation parameters and optimal stimulation intensity will be left to the discretion of the investigators during this experimental treatment. A range of the investigated stimulation parameters will be systematically recorded and will be reported as part of the methodology/study protocol. Participants will be continuously monitored and asked to provide any verbal feedback regarding their sensation of stimulation to ensure there is no pain or discomfort during treatment. For sham stimulation, electrodes will be placed in the same location. The participant will be continually monitored and given similar verbal cues as with the stimulation trials, but no electrical current will be delivered. Participants in both arms will be informed that they may or may not feel the stimulation. Vital signs will be captured during tSCS and peri-treatment (60 minutes pre- and post-), as well as surface electromyography (EMG). Exploratory Biomarker Assessments Pre- and Post- treatment Biospecimens for biomarkers will always be drawn after informed consent is signed. We will measure glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) in blood and CSF on the first day of stimulation prior to the first stimulation session (\~72 hours after injury) and on the final day of stimulation (treatment #5) after the last treatment. GFAP and UCH-L1 will be assayed at ZSFG on the Abbott Alinity I Immunoassay system. At those same 2 time points we will also conduct a global discovery proteomic assay on both plasma and CSF. We will use the commercially available high-throughput protein biomarker discovery platform based on Olink's Proximity Extension Assay (PEA), which reliably measures \>3,000 proteins using \<1mL of biofluid. Transcutaneous spinal cord stimulation has shown great promise in chronic spinal cord injury rehabilitation medicine through maximizing residual neural circuitry and harnessing neuroplasticity. STEP-RAISE will offer this innovative technology to SCI patients in the acute phase (within days of their injury) to establish the safety, feasibility, and proof-of-concept of this treatment in early recovery. STEP-RAISE offers a creative approach to bringing a rehabilitative intervention to the acute care bedside before the onset of neuro-rehabilitative plateau. This bedside, non-invasive technique has the potential to greatly improve the early management of SCI by offering a bridge to early mobilization which is not currently possible for SCI patients. Given the non-invasive, relatively inexpensive, and portable nature of the technology, tSCS can be deployed in resource limited areas upholding treatment equity for survivors of traumatic SCI. STEP-RAISE is an essential first step prior to a definitive efficacy trial of tSCS in the ICU. It will provide critical preliminary information that will allow our team to properly design and power such a trial, which if positive, could radically change the paradigm of early rehabilitation in the ICU and change standard of care.